XTANDI (ENZALUTAMIDE): A NEW TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Česká verzia

Authors: N. Shore
Published in the journal: Urol List 2013; 11(3): 18-20

Summary

Prostate cancer can return following initial surgical or radiation therapy intervention for localized disease. These men are usually treated with therapies aimed to lower their androgen levels. However, despite these efforts the prostate cancer oftentimes recurs. This recurrence, manifested by a rising PSA, is referred to as castration-resistant prostate cancer. Until recently, few treatment options were available to men with CRPC. Within the last three years, however, several new treatment options for patients with CRPC have become available, including Enzalutamide (XTANDI), the newest therapy approved in May 2012 for the treatment of metastatic CRPC following docetaxel. The author of this article aims to help patients understand how enzalutamide, an androgen receptor inhibitor, was designed and developed as a treatment for patients with CRPC.

Key words:
prostate cancer, castration-resistant, androgen receptor inhibitors

Zdroje

1. Nacusi LP, Tindall DJ. Androgen receptor abnormalities in castration-recurrent prostate cancer. Expert Rev Endocrinol Metab 2009; 4(5): 417–422.

2. Brinkmann AO. Chap 3: Androgen Physiology: Receptor and metabolic disorders in Receptor and Metabolic Disorders. Available from: http://www.endotext.org/male/male3/index.html. Accessed July 22, 2011.

3. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2010; 324: 787–790.

4. Scher HI, Beer TM, Higano CS et al; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 2010; 375: 1437–46.

5. Scher HI, Fizazi K, Saad F et al for the AFFIRM Investigators. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med 2012; 367: 1187–97.

Štítky

Paediatric urologist Urology

Článek DEFINING THE CANDIDATE FOR SURVEILLANCE OR TARGETED FOCAL THERAPY IN PROSTATE CANCER

Článek POST PROSTATECTOMY INCONTINENCE: A REVIEW OF CURRENT ASSESSMENT AND MANAGEMENT

Článek WHAT IS THE BENEFIT OF DENOSUMAB (XGEVA®) IN PATIENT WITH SOLID TUMOURS WITH BONE METASTASES?

Článek Holmium Laser Approaches to Symptomatic Benign Prostatic Hyperplasia

Článek PROGNOSTICS FACTORS, MOLECULAR MARKERS AND PREDICTIVE TOOLS IN UPPER TRACT UROTHELIAL CARCINOMA

Článek ENDOMETRIOSIS OF THE UROGENITAL TRACT

Článok vyšiel v časopise

Urological Journal

2013 Číslo 3

Najčítanejšie v tomto čísle